| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TMDXTransMedics Group, Inc. | 4.85B | 141.96 | 140.55 | 82.74% | 16.2% | 25.83% | 2.27 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.21M | 7.68M | 13.02M | 23.6M | 25.64M | 30.26M | 93.46M | 241.62M | 441.54M |
| Revenue Growth % | - | 0.24% | 0.69% | 0.81% | 0.09% | 0.18% | 2.09% | 1.59% | 0.83% |
| Cost of Goods Sold | 5.44M | 5.55M | 7.28M | 9.74M | 9M | 9.1M | 28.19M | 87.53M | 179.46M |
| COGS % of Revenue | 0.88% | 0.72% | 0.56% | 0.41% | 0.35% | 0.3% | 0.3% | 0.36% | 0.41% |
| Gross Profit | 766K | 2.14M | 5.73M | 13.86M | 16.64M | 21.16M | 65.27M | 154.09M | 262.08M |
| Gross Margin % | 0.12% | 0.28% | 0.44% | 0.59% | 0.65% | 0.7% | 0.7% | 0.64% | 0.59% |
| Gross Profit Growth % | - | 1.79% | 1.68% | 1.42% | 0.2% | 0.27% | 2.08% | 1.36% | 0.7% |
| Operating Expenses | 23.75M | 22.56M | 25.97M | 43.47M | 43.02M | 60.59M | 96.71M | 182.82M | 224.59M |
| OpEx % of Revenue | 3.83% | 2.94% | 2% | 1.84% | 1.68% | 2% | 1.03% | 0.76% | 0.51% |
| Selling, General & Admin | 8.12M | 7.61M | 12.31M | 23.6M | 24.19M | 38.28M | 69.9M | 119.55M | 168.62M |
| SG&A % of Revenue | 1.31% | 0.99% | 0.95% | 1% | 0.94% | 1.27% | 0.75% | 0.49% | 0.38% |
| Research & Development | 15.64M | 14.96M | 13.66M | 19.87M | 18.83M | 22.3M | 26.81M | 63.27M | 55.97M |
| R&D % of Revenue | 2.52% | 1.95% | 1.05% | 0.84% | 0.73% | 0.74% | 0.29% | 0.26% | 0.13% |
| Other Operating Expenses | 5K | 0 | -213K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -22.99M | -20.43M | -20.24M | -29.6M | -26.38M | -39.43M | -31.44M | -28.73M | 37.5M |
| Operating Margin % | -3.7% | -2.66% | -1.55% | -1.25% | -1.03% | -1.3% | -0.34% | -0.12% | 0.08% |
| Operating Income Growth % | - | 0.11% | 0.01% | -0.46% | 0.11% | -0.49% | 0.2% | 0.09% | 2.31% |
| EBITDA | -22.56M | -19.8M | -19.47M | -28.38M | -24.81M | -37.61M | -27.96M | -20.55M | 57.25M |
| EBITDA Margin % | -3.63% | -2.58% | -1.5% | -1.2% | -0.97% | -1.24% | -0.3% | -0.09% | 0.13% |
| EBITDA Growth % | - | 0.12% | 0.02% | -0.46% | 0.13% | -0.52% | 0.26% | 0.26% | 3.79% |
| D&A (Non-Cash Add-back) | 426K | 630K | 769K | 1.22M | 1.58M | 1.82M | 3.48M | 8.18M | 19.76M |
| EBIT | -23.09M | -19.72M | -21M | -29.15M | -24.73M | -40.3M | -32.44M | -15.88M | 50.19M |
| Net Interest Income | -974K | -524K | -2.42M | -3.56M | -2.33M | -3.87M | -2.83M | 1.71M | -14.41M |
| Interest Income | 5K | 548K | 0 | 790K | 1.65M | 0 | 900K | 12.5M | 0 |
| Interest Expense | 979K | 1.07M | 2.42M | 4.35M | 3.98M | 3.87M | 3.73M | 10.79M | 14.41M |
| Other Income/Expense | -1.08M | -365K | -3.48M | -3.9M | -2.33M | -4.75M | -4.73M | 2.06M | -1.72M |
| Pretax Income | -24.07M | -20.79M | -23.71M | -33.51M | -28.72M | -44.18M | -36.16M | -26.67M | 35.78M |
| Pretax Margin % | -3.88% | -2.71% | -1.82% | -1.42% | -1.12% | -1.46% | -0.39% | -0.11% | 0.08% |
| Income Tax | 0 | 32K | 41K | 40K | 32K | 36K | 66K | -1.64M | 316K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 0.94% | 0.99% |
| Net Income | -24.07M | -20.82M | -23.76M | -33.55M | -28.75M | -44.22M | -36.23M | -25.03M | 35.46M |
| Net Margin % | -3.88% | -2.71% | -1.82% | -1.42% | -1.12% | -1.46% | -0.39% | -0.1% | 0.08% |
| Net Income Growth % | - | 0.13% | -0.14% | -0.41% | 0.14% | -0.54% | 0.18% | 0.31% | 2.42% |
| Net Income (Continuing) | -24.07M | -20.82M | -23.76M | -33.55M | -28.75M | -44.22M | -36.23M | -25.03M | 35.46M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.66 | -1.44 | -1.23 | -2.36 | -1.16 | -1.60 | -1.23 | -0.77 | 1.01 |
| EPS Growth % | - | 0.13% | 0.15% | -0.92% | 0.51% | -0.38% | 0.23% | 0.37% | 2.31% |
| EPS (Basic) | -1.66 | -1.44 | -1.23 | -2.36 | -1.16 | -1.60 | -1.23 | -0.77 | 1.07 |
| Diluted Shares Outstanding | 14.48M | 14.48M | 19.25M | 14.2M | 24.7M | 27.62M | 29.56M | 32.52M | 35.22M |
| Basic Shares Outstanding | 14.48M | 14.48M | 19.25M | 14.2M | 24.7M | 27.62M | 29.56M | 32.52M | 33.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 55.86M | 34.04M | 34.79M | 100M | 146.77M | 118.7M | 252.29M | 510.65M | 497.22M |
| Cash & Short-Term Investments | 47.84M | 24.66M | 20.24M | 80.69M | 125.64M | 92.45M | 201.18M | 394.81M | 336.65M |
| Cash Only | 9.84M | 11.94M | 20.24M | 20.09M | 24.58M | 25.58M | 201.18M | 394.81M | 336.65M |
| Short-Term Investments | 38M | 12.73M | 0 | 60.6M | 101.06M | 66.87M | 0 | 0 | 0 |
| Accounts Receivable | 1.38M | 925K | 3.44M | 6.56M | 6.86M | 5.93M | 27.61M | 63.58M | 97.72M |
| Days Sales Outstanding | 81.07 | 43.93 | 96.4 | 101.42 | 97.72 | 71.57 | 107.83 | 96.04 | 80.78 |
| Inventory | 6.33M | 7.97M | 9.28M | 11.22M | 11.93M | 14.86M | 20.61M | 44.23M | 46.55M |
| Days Inventory Outstanding | 424.82 | 524.41 | 464.93 | 420.27 | 483.77 | 595.8 | 266.82 | 184.46 | 94.69 |
| Other Current Assets | 0 | 0 | 0 | 1.54M | 2.33M | 5.46M | 2.9M | 8.03M | 16.29M |
| Total Non-Current Assets | 2.24M | 2.96M | 7.36M | 5.3M | 5.26M | 16.19M | 24.85M | 195.39M | 306.86M |
| Property, Plant & Equipment | 1.72M | 2.46M | 3.47M | 4.79M | 4.75M | 15.69M | 24.35M | 180.49M | 292.45M |
| Fixed Asset Turnover | 3.60x | 3.13x | 3.75x | 4.93x | 5.39x | 1.93x | 3.84x | 1.34x | 1.51x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.99M | 11.55M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.35M | 2.15M |
| Long-Term Investments | 0 | 500K | 500K | 500K | 0 | 500K | 500K | 0 | 0 |
| Other Non-Current Assets | 518K | 6K | 3.39M | 6K | 506K | 0 | 0 | 562K | 708K |
| Total Assets | 58.1M | 37M | 42.16M | 105.3M | 152.03M | 134.89M | 277.15M | 706.05M | 804.08M |
| Asset Turnover | 0.11x | 0.21x | 0.31x | 0.22x | 0.17x | 0.22x | 0.34x | 0.34x | 0.55x |
| Asset Growth % | - | -0.36% | 0.14% | 1.5% | 0.44% | -0.11% | 1.05% | 1.55% | 0.14% |
| Total Current Liabilities | 9.47M | 10.9M | 12.55M | 16.11M | 11.88M | 23.24M | 23.66M | 54.93M | 59.91M |
| Accounts Payable | 4.25M | 3.52M | 4.72M | 7.25M | 1.21M | 6.65M | 3.34M | 12.72M | 10.29M |
| Days Payables Outstanding | 285 | 231.25 | 236.55 | 271.55 | 48.89 | 266.68 | 43.26 | 53.03 | 20.93 |
| Short-Term Debt | 0 | 1.8M | 0 | 0 | 0 | 0 | 0 | 0 | 2.73M |
| Deferred Revenue (Current) | 0 | 239K | 306K | 166K | 263K | 250K | 241K | 1000K | 1000K |
| Other Current Liabilities | 488K | 569K | 655K | 370K | 6.38M | 11.16M | 8.82M | 17.92M | 45.15M |
| Current Ratio | 5.90x | 3.12x | 2.77x | 6.21x | 12.36x | 5.11x | 10.66x | 9.30x | 8.30x |
| Quick Ratio | 5.23x | 2.39x | 2.03x | 5.51x | 11.35x | 4.47x | 9.79x | 8.49x | 7.52x |
| Cash Conversion Cycle | 220.88 | 337.09 | 324.78 | 250.15 | 532.6 | 400.69 | 331.39 | 227.47 | 154.53 |
| Total Non-Current Liabilities | 9.84M | 194.83M | 34.43M | 34.53M | 36.26M | 43.8M | 66.11M | 513.91M | 515.56M |
| Long-Term Debt | 8.41M | 6.85M | 33.67M | 34.15M | 34.66M | 35.2M | 58.7M | 506.2M | 509.31M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 8.6M | 7.42M | 7.71M | 6.25M |
| Deferred Tax Liabilities | 0 | -1.11M | -759K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.44M | 187.98M | 759K | 389K | 1.6M | 0 | 0 | 0 | 0 |
| Total Liabilities | 19.32M | 205.72M | 46.98M | 50.65M | 48.13M | 67.04M | 89.77M | 568.85M | 575.47M |
| Total Debt | 8.41M | 8.65M | 33.67M | 34.15M | 34.66M | 43.8M | 67.56M | 515.95M | 518.29M |
| Net Debt | -1.43M | -3.28M | 13.43M | 14.05M | 10.08M | 18.22M | -133.63M | 121.13M | 181.64M |
| Debt / Equity | 0.22x | - | - | 0.62x | 0.33x | 0.65x | 0.36x | 3.76x | 2.27x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 9.05x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 3.17x |
| Interest Coverage | -23.48x | -19.05x | -8.36x | -6.80x | -6.62x | -10.18x | -8.44x | -2.66x | 2.60x |
| Total Equity | 38.79M | -168.72M | -4.83M | 54.65M | 103.89M | 67.85M | 187.38M | 137.2M | 228.6M |
| Equity Growth % | - | -5.35% | 0.97% | 12.33% | 0.9% | -0.35% | 1.76% | -0.27% | 0.67% |
| Book Value per Share | 2.68 | -11.65 | -0.25 | 3.85 | 4.21 | 2.46 | 6.34 | 4.22 | 6.49 |
| Total Shareholders' Equity | 38.79M | -168.72M | -4.83M | 54.65M | 103.89M | 67.85M | 187.38M | 137.2M | 228.6M |
| Common Stock | 1K | 1K | 331.21M | 424.13M | 502.22M | 510.49M | 666.28M | 641.11M | 697.21M |
| Retained Earnings | -291.36M | -312.18M | -335.94M | -369.48M | -398.23M | -442.45M | -478.68M | -503.7M | -468.24M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -417K | -149K | -101K | -2K | -95K | -188K | -225K | -199K | -364K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -24.11M | -23.1M | -25.98M | -32.29M | -30.27M | -28.86M | -45.82M | -13.03M | 48.8M |
| Operating CF Margin % | -3.88% | -3.01% | -2% | -1.37% | -1.18% | -0.95% | -0.49% | -0.05% | 0.11% |
| Operating CF Growth % | - | 0.04% | -0.12% | -0.24% | 0.06% | 0.05% | -0.59% | 0.72% | 4.75% |
| Net Income | -24.07M | -20.82M | -23.76M | -33.55M | -28.75M | -44.22M | -36.23M | -25.03M | 35.46M |
| Depreciation & Amortization | 426K | 630K | 769K | 1.22M | 1.58M | 1.82M | 3.48M | 8.18M | 19.76M |
| Stock-Based Compensation | 45K | 70K | 144K | 854K | 2.41M | 6.88M | 10.32M | 19.79M | 33.22M |
| Deferred Taxes | 292K | -316K | 1.01M | 336K | -431K | 0 | 0 | -1.66M | 0 |
| Other Non-Cash Items | 65K | 93K | 177K | 475K | 511K | 3.65M | 3.37M | 30.04M | 5.36M |
| Working Capital Changes | -872K | -2.75M | -4.33M | -1.63M | -5.59M | 3M | -26.76M | -44.35M | -45M |
| Change in Receivables | -758K | 454K | -2.51M | -3.17M | -218K | 840K | -21.68M | -33.82M | -34.31M |
| Change in Inventory | -1.59M | -2.5M | -2.7M | -4.12M | -1.74M | -4.89M | -8.02M | -28.09M | -8.35M |
| Change in Payables | 1.06M | -735K | 164K | 3.44M | -5.8M | 5.09M | -3.27M | 6.96M | -1.4M |
| Cash from Investing | -39.67M | 24.86M | 12.31M | -60.5M | -41.6M | 29.27M | 54.51M | -193.95M | -129.3M |
| Capital Expenditures | -1.48M | -263K | -418K | -165K | -455K | -3.52M | -11.91M | -151.85M | 0 |
| CapEx % of Revenue | 0.24% | 0.03% | 0.03% | 0.01% | 0.02% | 0.12% | 0.13% | 0.63% | 0.29% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -38.19M | 25.12M | 12.72M | -60.34M | -41.14M | 0 | -107K | -27.21M | -129.74M |
| Cash from Financing | 63.54M | 3K | 22.06M | 92.72M | 75.55M | 1.39M | 167.93M | 400.42M | 22.87M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | -64K | 3K | -2.3M | -4.64M | 584K | 1.39M | 5.61M | -44.96M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -25.59M | -23.36M | -26.4M | -32.45M | -30.72M | -32.38M | -57.72M | -192.09M | -80.94M |
| FCF Margin % | -4.12% | -3.04% | -2.03% | -1.37% | -1.2% | -1.07% | -0.62% | -0.79% | -0.18% |
| FCF Growth % | - | 0.09% | -0.13% | -0.23% | 0.05% | -0.05% | -0.78% | -2.33% | 0.58% |
| FCF per Share | -1.77 | -1.61 | -1.37 | -2.28 | -1.24 | -1.17 | -1.95 | -5.91 | -2.30 |
| FCF Conversion (FCF/Net Income) | 1.00x | 1.11x | 1.09x | 0.96x | 1.05x | 0.65x | 1.26x | 0.52x | 1.38x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 3.33M | 0 | 8.09M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -62.04% | - | - | -134.66% | -36.27% | -51.49% | -28.39% | -15.42% | 19.39% |
| Return on Invested Capital (ROIC) | - | - | -176.4% | -57.44% | -21.67% | -29.56% | -33.73% | -13.81% | 8.41% |
| Gross Margin | 12.34% | 27.81% | 44.05% | 58.73% | 64.88% | 69.92% | 69.84% | 63.77% | 59.36% |
| Net Margin | -387.58% | -270.96% | -182.5% | -142.12% | -112.13% | -146.11% | -38.77% | -10.36% | 8.03% |
| Debt / Equity | 0.22x | - | - | 0.62x | 0.33x | 0.65x | 0.36x | 3.76x | 2.27x |
| Interest Coverage | -23.48x | -19.05x | -8.36x | -6.80x | -6.62x | -10.18x | -8.44x | -2.66x | 2.60x |
| FCF Conversion | 1.00x | 1.11x | 1.09x | 0.96x | 1.05x | 0.65x | 1.26x | 0.52x | 1.38x |
| Revenue Growth | - | 23.77% | 69.38% | 81.33% | 8.62% | 18.03% | 208.83% | 158.53% | 82.74% |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Product | - | - | - | 79.23M | 176.05M | 273.87M |
| Product Growth | - | - | - | - | 122.19% | 55.56% |
| Service Revenue | - | - | - | 14.22M | 65.55M | 167.67M |
| Service Revenue Growth | - | - | - | - | 360.84% | 155.78% |
| Ocs Heart Product | 11.44M | 14.2M | 17.68M | - | - | - |
| Ocs Heart Product Growth | - | 24.07% | 24.56% | - | - | - |
| Ocs Lung Product | 8.66M | 6.19M | 10.66M | - | - | - |
| Ocs Lung Product Growth | - | -28.51% | 72.18% | - | - | - |
| Ocs Liver Product | 3.5M | 5.25M | 1.91M | - | - | - |
| Ocs Liver Product Growth | - | 50.06% | -63.54% | - | - | - |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| UNITED STATES | 16.25M | 19.24M | 21.86M | 7.97M | - | - |
| UNITED STATES Growth | - | 18.37% | 13.63% | -63.56% | - | - |
| Other Countries | 3.97M | - | - | 880K | - | - |
| Other Countries Growth | - | - | - | - | - | - |
| Non Us And Uk | - | 6.4M | 8.4M | - | - | - |
| Non Us And Uk Growth | - | - | 31.27% | - | - | - |
| GERMANY | 1.15M | - | - | - | - | - |
| GERMANY Growth | - | - | - | - | - | - |
TransMedics Group, Inc. (TMDX) has a price-to-earnings (P/E) ratio of 140.6x. This suggests investors expect higher future growth.
TransMedics Group, Inc. (TMDX) reported $566.4M in revenue for fiscal year 2024. This represents a 9022% increase from $6.2M in 2016.
TransMedics Group, Inc. (TMDX) grew revenue by 82.7% over the past year. This is strong growth.
Yes, TransMedics Group, Inc. (TMDX) is profitable, generating $91.8M in net income for fiscal year 2024 (8.0% net margin).
TransMedics Group, Inc. (TMDX) has a return on equity (ROE) of 19.4%. This is reasonable for most industries.
TransMedics Group, Inc. (TMDX) generated $120.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.